Monte Rosa to present Phase 1 GFORCE-1 data for MRT-8102 in elevated cardiovascular risk subjects
Bitget2026/09/30 20:01- Monte Rosa Therapeutics scheduled an Oct. 1 webcast to present Phase 1 GFORCE-1 results for MRT-8102 in elevated cardiovascular risk subjects.
- Results have not yet been presented; management plans to disclose safety and activity findings across multiple dose levels following four weeks of treatment.
- The update is expected to highlight evidence of broad modulation of disease-driving processes linked to atherosclerotic cardiovascular disease.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro gains against Canadian Dollar ahead of Eurozone HICP data
Major European stock indices open collectively higher
Broadcom (AVGO.US) syndicate begins raising 60 billions USD to supply chip "ammunition" for companies like Anthropic
According to informed sources, Broadcom's Wall Street syndicate is initiating the raising of $60 billion in new financing to purchase artificial intelligence (AI) chips, with beneficiaries including Anthropic PBC and other companies.
BICO completes integration of Cellenion into SCIENION, retires Cellenion brand
Crypto prices
More
